Member Info for BuilderPete

Watching now ,further raises the profile of Hydrogen.
L&G so should be a GBP product.

Testing seems to be the only way to corner this virus huge amounts of people across the globe will have no vaccine before 2023 and that does not include having to re -vaccinate people again against the new variants.

Hardly ever turns up on a Friday and have found some pages do not load fully up on the digital version .
Still prefer to read the paper copy .

“Taking COVID tests at work will pave the way to a better year”.

Looks like the SP is being punished for perception that tests( as per NOVACYT) will not be needed after this year .
First of all we have not risen on the increase in turnover (45%) so nothing was added in value for that and testing perhaps will not peak until 2022 or beyond in the markets we sell to .
Nobody is saying that the vaccines will end this pandemic and no vaccine has been approved for the under 18s so testing will be one of the means of control for a long time yet.
Looks like ST has been extremely busy as he has a huge section in IC this month.
Lastly COVID testing has been an unforeseen bonus for this company which has masked the technology we all originally invested here for all of which has further huge potential in excess of the Covid testing income.

Or a week late if you live where I do !!

Every day there has been significantly more buys than sells so at some point someone buying is going to run out of shares to buy.

My paper copy usually turns up a week late courtesy of the PO good job I coughed for the digital copy as well.

Every day showing more buys than sells so has to give at some point.

Think we will get a run up towards Feb 22nd.

Wingates Chindits suffered terribly in their fight against the Japanese dysentery/malaria and the jungle took a huge toll on them,anyone who was out there deserves our greatest respect.

Looking like $75m of free cash once the sale goes through.
This jump in turnover does not include the NFV time royalties which are expected to run into the hundred of millions .
The more you look at this share the more you can see it is majorly undervalued.
Check out the Zvi Marom interview on pro -active investors everything about it suggests this company has only just started to realise its potential.

Is on proactive investors already.

Feels like we will see a nice gradual rise into Feb 22nd as the last RNS sinks in .
Interesting to see what sort of profit margin is coming out of the $180 m turnover and how progressive the dividend policy will be .
As I have said before there are so many aspects to this company the year end report may well take a while to read and digest but at least it’s something to look forward to in the current climate.

Patience will be rewarded here .

Look out for ST a update on this and VLG at some point.

Revenue of $180 m at least puts us on track to a £1 b company by market value.
As I have said before testing is going nowhere for a long time as no vaccines are approved for the under 18s anywhere in the world.
Just going to add more b4 scoot off to work.

Novacyt turnover up 20x on COVID test supply and that’s just one part of this company.!!!!

That ignores the fact that shorters have sniffed out fraudulent companies way before the regulators Wirecard being a recent example.

Hope that is socially distanced coffee!!!!